<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01441206</url>
  </required_header>
  <id_info>
    <org_study_id>10-2314</org_study_id>
    <secondary_id>1K23HD068497-01</secondary_id>
    <nct_id>NCT01441206</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants</brief_title>
  <official_title>Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about the safety and dosing of rifampin in
      infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetics and safety of rifampin will be studied in term and preterm infants who are
      receiving rifampin per standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study to be redesigned.
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve 0-24 hours for rifampin</measure>
    <time_frame>Sampling for 24 hr dosing:Dose 1:0-15min,30-60min,1-3hr,3-6hr, 6-12hr,12-18hr. Dose 2,3 or 4:&lt;15min prior to dose, 48-72hrs. Sampling for 12 hr dosing:Dose 1: 0-15min, 0.5-1hr, 1-2hr, 2-4hr, 5-8hr, 8-10 hr. Dose 2, 3 or 4:&lt;15min prior to dose, 24-36hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration of rifampin</measure>
    <time_frame>Sampling for 24 hr dosing:Dose 1:0-15min,30-60min,1-3hr,3-6hr, 6-12hr,12-18hr. Dose 2,3 or 4:&lt;15min prior to dose, 48-72hrs. Sampling for 12 hr dosing:Dose 1: 0-15min, 0.5-1hr, 1-2hr, 2-4hr, 5-8hr, 8-10 hr. Dose 2, 3 or 4:&lt;15min prior to dose, 24-36hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of rifampin</measure>
    <time_frame>Sampling for 24 hr dosing:Dose 1:0-15min,30-60min,1-3hr,3-6hr, 6-12hr,12-18hr. Dose 2,3 or 4:&lt;15min prior to dose, 48-72hrs. Sampling for 12 hr dosing:Dose 1: 0-15min, 0.5-1hr, 1-2hr, 2-4hr, 5-8hr, 8-10 hr. Dose 2, 3 or 4:&lt;15min prior to dose, 24-36hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution at steady state</measure>
    <time_frame>Sampling for 24 hr dosing:Dose 1:0-15min,30-60min,1-3hr,3-6hr, 6-12hr,12-18hr. Dose 2,3 or 4:&lt;15min prior to dose, 48-72hrs. Sampling for 12 hr dosing:Dose 1: 0-15min, 0.5-1hr, 1-2hr, 2-4hr, 5-8hr, 8-10 hr. Dose 2, 3 or 4:&lt;15min prior to dose, 24-36hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life of rifampin</measure>
    <time_frame>Sampling for 24 hr dosing:Dose 1:0-15min,30-60min,1-3hr,3-6hr, 6-12hr,12-18hr. Dose 2,3 or 4:&lt;15min prior to dose, 48-72hrs. Sampling for 12 hr dosing:Dose 1: 0-15min, 0.5-1hr, 1-2hr, 2-4hr, 5-8hr, 8-10 hr. Dose 2, 3 or 4:&lt;15min prior to dose, 24-36hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability.</measure>
    <time_frame>From the time of the first dose to 3 days after the last dose; serious adverse events will be collected from the first dose of rifampin to 7 days after the last dose of rifampin.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>rifampin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 1 will include infants who will be receiving up to 4 doses rifampin per study protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rifampin per standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Cohort 2: Receiving rifampin per standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampin</intervention_name>
    <description>Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)
Cohort 1:
Dosing will be as follows:
GA at birth &lt; 32 weeks - PNA &lt; 14 days: 10 mg/kg QD GA at birth &lt; 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA &lt; 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD</description>
    <arm_group_label>rifampin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Cohort 1:

          -  Suspected systemic infection

          -  Infant &lt; 121 days of age at the time of 1st dose of rifampin administration

          -  Sufficient intravascular access (either peripheral or central) to receive rifampin.

        Cohort 2:

          -  Receiving rifampin per local standard of care.

          -  Infant &lt; 121 days of age at the time of 1st dose of rifampin administration

        Exclusion Criteria:

        Cohort 1:

          -  History of allergic reactions to rifampin

          -  Aspartate aminotransferase (AST) greater than 3 times upper limit of normal

          -  Alanine aminotransferase (ALT) greater than 3 times upper limit of normal

          -  Serum creatinine greater than 1.7 mg.dL

          -  Urine output &lt; 0.5 mL/hr/kg over the prior 24 hours

          -  Any condition which would make the subject, in the opinion of the investigator,
             unsuitable for the study

        Cohort 2:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>121 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew M. Laughon, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2011</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rifampin</keyword>
  <keyword>infants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

